盟科药业跌4.4% 2022年上市即巅峰募10.6亿元

Core Viewpoint - Mengke Pharmaceutical (688373.SH) is currently experiencing a decline in stock price, closing at 7.38 yuan with a drop of 4.40%, resulting in a total market capitalization of 4.838 billion yuan, indicating the stock is in a state of loss since its IPO [1] Group 1: IPO Details - Mengke Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 5, 2022, with an initial public offering (IPO) of 130 million shares at a price of 8.16 yuan per share [1] - The stock reached a peak price of 14.20 yuan on its first trading day, marking the highest price since its listing [1] - The total funds raised from the IPO amounted to 1.0608 billion yuan, with a net amount of 959.7279 million yuan after deducting issuance costs, which was 290.1495 million yuan less than the original plan [1] Group 2: Fund Allocation - The company initially planned to raise 1.2498774 billion yuan, which was intended for innovative drug research and development, marketing channel upgrades, academic promotion projects, and to supplement working capital [1] - The total issuance costs for the IPO were 101.0721 million yuan, with underwriting and sponsorship fees accounting for 79.0296 million yuan [1]